


Amendments to the Claims


A full listing of the claims is as follows:

1-3. (Canceled)


4. (Currently amended) An indirubin compound having an anti-proliferative property to a human cancer cell line selected from the group consisting of a human lung cancer cell line, a human stomach cancer cell line, a human colon cancer cell line, a human abdominal cavity cancer cell line, and a human leukemia cell line; and having a property for inducing apoptosis to a leukemia cell line by inducing differentiation as CDK inhibitor representing the following formula:




5. (Currently amended) An indirubin compound having an anti-proliferative property to a human cancer cell line selected from the group consisting of a human lung cancer cell line, a human stomach cancer cell line, a human colon cancer cell line, a human abdominal cavity cancer cell line, and a human leukemia cell line; and having a property for inducing apoptosis to a leukemia cell line by inducing differentiation as CDK inhibitor representing the following formula:




6. (Currently amended) An indirubin compound having an anti-proliferative property to a human cancer cell line selected from the group consisting of a human lung cancer cell line, a human stomach cancer cell line, a human colon cancer cell line, a human abdominal cavity cancer cell line, and a human leukemia cell line; and having a property for inducing apoptosis to a leukemia cell line by inducing differentiation as CDK inhibitor representing the following formula:



7. (Currently amended) An indirubin compound having an anti-proliferative property to a human cancer cell line selected from the group consisting of a human lung cancer cell line, a human stomach cancer cell line, a human colon cancer cell line, a human abdominal cavity cancer cell line, and a human leukemia cell line; and having a property for inducing apoptosis to a leukemia cell line by inducing differentiation as CDK inhibitor representing the following formula:



8. (Currently amended) An indirubin compound having an anti-proliferative property to a human cancer cell line selected from the group consisting of a human lung cancer cell line, a human stomach cancer cell line, a human colon cancer cell line, a human abdominal cavity cancer cell line, and a human leukemia cell line; and having a property for inducing apoptosis to a leukemia cell line by inducing differentiation as CDK inhibitor representing the following formula:



9. (Previously presented) A composition comprising 0.1 – 80 wt% of the compound of claim 4 and a pharmaceutically acceptable carrier.

10. (Previously presented) The composition according to claim 9 in the form of an injection formulation, capsule, tablet, solution, or pellet.

11. (Previously presented) A composition comprising 0.1 – 80 wt% of the compound of claim 5 and a pharmaceutically acceptable carrier.

12. (Previously presented) The composition according to claim 11 in the form of an injection formulation, capsule, tablet, solution, or pellet.

13. (Previously presented) A composition comprising 0.1 – 80 wt% of the compound of claim 6 and a pharmaceutically acceptable carrier.

14. (Previously presented) The composition according to claim 13 in the form of an injection formulation, capsule, tablet, solution, or pellet.

15. (Previously presented) A composition comprising 0.1 – 80 wt% of the compound of claim 7 and a pharmaceutically acceptable carrier.

16. (Previously presented) The composition according to claim 15 in the form of an injection formulation, capsule, tablet, solution, or pellet.
17. (Previously presented) A composition comprising 0.1 – 80 wt% of the compound of claim 8 and a pharmaceutically acceptable carrier.
18. (Previously presented) The composition according to claim 17 in the form of an injection formulation, tablet, solution, or pellet.